TABLE 2.

Clinical Data and SUVs of Study Population

Patient no.					Clinical symptoms				Σ SUV_max			Σ SUV_T/S
Patient no.	Sex	Age (y)	Primary tumor	Previous therapies	Baseline	FU	SSA	SUV_max	Baseline	FU	ΔSUV_max	Baseline	FU	ΔSUV_T/S	TTP
1	M	44	Lung	Surgery	Yes	Imp.	Yes	19.4	54.9	62.4	13.7	2.83	2.81	−0.7	NR
2	F	61	Paraganglioma	Surgery, radiation	Yes	NC	Yes	22.4	75.5	71.0	−6.0	3.37	3.43	1.8	NR
3	M	52	CUP	None	Yes	NC	Yes	23.8	77.1	81.4	5.6	3.72	3.63	−2.4	NR
4	M	62	Pancreas	Surgery	Yes	Imp.	Yes	38.4	127.4	102.2	−19.8	6.28	5.03	−19.8	12
5	M	72	Pancreas	None	No	No	No	26.0	32.1	26.0	−19.0	1.55	1.02	−34.5	NR
6	F	49	Retroperitoneal	Surgery, SSA	Yes	Imp.	Yes	42.6	136.8	58.3	−57.4	6.84	2.60	−61.9	NR
7	M	44	Paranasal sinus	Surgery, radiation, chemotherapy	Yes	NC	Yes	18.1	51.7	70.0	35.4	1.48	2.27	53.9	3
8	F	62	Stomach	Surgery	Yes	Imp.	Yes	56.8	138.0	96.4	−30.1	7.50	4.42	−41.0	NR
9	F	57	CUP	None	No	No	No	35.7	163.2	114.9	−29.6	6.61	4.58	−30.7	NR
10	M	68	Ileum	Surgery	Yes	NC	Yes	30.2	88.5	117.1	32.3	3.88	4.01	3.3	8
11	M	68	Pancreas	Surgery, RFA	Yes	Imp.	Yes	46.7	127.9	40.8	−68.1	6.30	1.15	−81.8	NR
12	F	72	Rectum	Surgery, PRRT	No	No	No	6.7	22.9	25.9	13.1	1.21	1.07	−10.8	NR
13	M	70	Lung	Surgery, chemotherapy, SSA, radiation, RFA, TACE	No	No	No	14.3	41.1	45.8	11.4	5.71	6.27	9.9	3
14	M	70	Ileum	Chemotherapy	Yes	Imp.	Yes	25.5	69.6	63.1	−9.3	3.89	4.54	16.8	NR
15	M	60	Lung	Surgery	No	No	No	82.7	314.9	138.9	−55.9	11.13	9.71	−12.7	NR
16	M	63	Pancreas	None	No	No	No	48.5	108.2	73.9	−31.7	11.51	3.55	−69.1	NR
17	M	62	Lung	Surgery	No	No	No	33.6	154.1	44.2	−71.3	12.33	3.09	−74.9	11
18	M	57	Pancreas	None	Yes	NC	Yes	21.1	81.8	115.6	41.3	6.82	9.03	32.5	10
19	M	51	Rectum	Surgery, chemotherapy, TACE, SSA	No	No	No	34.1	79.7	36.4	−54.3	2.68	2.51	−6.5	16
20	M	63	Ileum	RFA	Yes	NC	Yes	17.0	79.9	92.2	15.4	7.83	6.45	−17.7	NR
21	F	250	Ileum	Surgery	No	No	No	16.0	36.7	30.1	−18.0	2.03	1.51	−25.8	12
22	F	42	Ileum	Surgery, TACE, SSA	No	No	No	36.5	163.3	79.8	−51.1	12.19	6.65	−45.4	14
23	M	20	Pancreas	Surgery, chemotherapy, MIBG therapy, SSA	No	No	No	9.4	23.7	53.9	127.4	4.74	7.49	57.9	3
24	M	49	Ileum	Surgery, SIRT, SSA, chemotherapy	Yes	NC	Yes	11.6	58.5	85.9	46.8	9.00	10.48	16.4	6
25	M	53	Rectum	Surgery, PRRT, SSA, radiation	No	No	No	15.4	37.5	65.8	75.5	2.91	2.40	−17.4	14
26	F	66	Ileum	Surgery	No	No	No	38.2	47.0	38.5	−18.1	2.23	1.24	−44.4	NR
27	M	72	Jejunum	Surgery, SSA, INF	No	No	No	36.7	132.2	147.9	11.9	6.09	5.85	−4.0	NR
28	F	67	Pancreas	Surgery	No	No	No	28.1	120.5	41.3	−65.7	18.54	4.44	−76.0	13
29	F	33	Pancreas	Surgery	Yes	Imp.	Yes	25.3	35.3	31.3	−11.3	3.43	2.22	−35.2	NR
30	F	54	Pancreas	Surgery, chemotherapy	No	No	No	9.5	76.6	104.2	36.0			NM	6
31	F	55	Stomach	Surgery, SIRT	Yes	Imp.	Yes	18.8	97.7	126.5	29.5			NM	NR
32	M	66	Ileum	Surgery	Yes	Imp.	Yes	27.7	44.8	59.6	33.0	3.90	2.42	−37.8	NR
33	M	72	Ileum	Surgery, SIRT	Yes	NC	Yes	24.2	116.4	114.0	−2.1	4.87	3.84	−21.2	6

SSA = somatostatin analogues; Σ = sum; FU = follow-up; Imp. = improvement; NR =TTP not reached; NC = no change; CUP = carcinoma of unknown primary; RFA = radiofrequency ablation; TACE = transarterial chemoembolization; MIBG = metaiodobenzylguanidine; SIRT = selective internal radiation therapy; INF = interferon alpha; NM = not measurable.